Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

About the trial

Sponsor

AbbVie

Tested

Risankizumab (drug)

Dates

Started 2021-07-24; completion 2028-04

Results posted

Not yet

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in disease activity with risankizumab in pediatric participants with moderate to severe plaque psoriasis who completed the study M19-977. Risankizumab is an approved drug for treatment of moderate to severe plaque psoriasis in adults and is being studied in the pediatric population (6 to 17 years). A maximum of 132 participants will be enrolled in the study across approximately 50 sites worldwide. Participants will receive subcutaneous injection of risankizumab every 12 weeks for 204 weeks and are fol…

From ClinicalTrials.gov, last updated 2025-08-12. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $196,147 in research payments for this study in 2025 (83 payments).

Products named: Skyrizi

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.